Investors Face November Deadline in Hims & Hers Securities Fraud Suit

The lawsuit, filed by the Rosen Law Firm, claims Hims & Hers misled shareholders by failing to disclose that it shared sensitive consumer health data with third-party advertising platforms. Furthermore, the complaint alleges the company charged customers for prescriptions almost immediately after intake forms were submitted, contradicting public assurances that patients would consult with medical providers to determine the most appropriate treatment.

These practices allegedly exposed the company to significant regulatory scrutiny, potential penalties, and financial risk, which were not properly communicated to the market. The lawsuit asserts that when these details surfaced, investors suffered financial losses. While a class action has been initiated, no class has yet been certified. Investors currently have the option to retain their own counsel, remain as absent class members, or move the court to serve as a lead plaintiff by the November deadline.